FTSE 100 movers: AstraZeneca gains; Barratt hit by MJ Gleeson update
London's FTSE 100 was flat at 8,824.61 in quiet afternoon trade on Friday, with US markets closed for Independence Day.
AstraZeneca gained after saying that its Imfinzi asset has been approved in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer.
Housebuilder Barratt Redrow was in the red after MJ Gleeson delivered a cautious outlook. The low-cost, affordable housebuilder said the housing market "lacks confidence and remains subdued".
"The board does not see a short-term catalyst for any substantial improvement," it said.
FTSE 100 - Risers
Vodafone Group (VOD) 81.76p 3.18%
Fresnillo (FRES) 1,484.00p 1.64%
Coca-Cola HBC AG (CDI) (CCH) 4,012.00p 1.21%
Coca-Cola Europacific Partners (DI) (CCEP) 7,040.00p 0.72%
AstraZeneca (AZN) 10,270.00p 0.65%
Centrica (CNA) 159.30p 0.63%
Rolls-Royce Holdings (RR.) 960.40p 0.63%
Haleon (HLN) 375.10p 0.54%
GSK (GSK) 1,400.50p 0.47%
Associated British Foods (ABF) 2,081.00p 0.43%
FTSE 100 - Fallers
Smurfit Westrock (DI) (SWR) 3,411.00p -2.46%
Mondi (MNDI) 1,199.00p -2.32%
Schroders (SDR) 363.40p -2.05%
Airtel Africa (AAF) 178.60p -1.92%
Intermediate Capital Group (ICG) 1,923.00p -1.89%
Barratt Redrow (BTRW) 425.80p -1.84%
Croda International (CRDA) 2,993.00p -1.77%
Babcock International Group (BAB) 1,067.00p -1.75%
Anglo American (AAL) 2,205.00p -1.74%
easyJet (EZJ) 522.80p -1.66%
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.